Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYL3C + indocyanine green
- Development stage
- Preclinical
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
SYL3C + indocyanine green (SYL3C-ICG) is an aptamer-conjugated near-infrared II (NIR-II) fluorescence imaging probe developed for the intraoperative visualization of tumor margins during breast cancer surgery. The compound consists of the DNA aptamer SYL3C, which specifically targets the Epithelial Cell Adhesion Molecule (EpCAM) overexpressed on cancer cells, conjugated with PEGylated indocyanine green (PEG-ICG). As a diagnostic imaging agent, it utilizes the NIR-II window (1000–1700 nm) to provide superior imaging resolution and deeper tissue penetration compared to traditional NIR-I imaging. This targeted molecular probe is designed to assist surgeons in identifying residual malignant lesions in real-time during surgical resection, potentially reducing postoperative recurrence rates.
- Other names
- SYL3C-PEG-ICGSYL-3C-PEG-ICGSYL 3C-PEG-ICG
02
Targets
EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on SYL3C + indocyanine green.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYL3C + indocyanine green.